SLC5A2 and type 2 diabetes mellitus: Urinary L-FABP, a biomarker of tubulointerstitial injury of the kidneys, was also significantly reduced in the low-eGFR group of the current study, although similar results were also observed when another SGLT2 inhibitor was administered to patients with type 2 diabetes [11].